Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) Trial

被引：0
|
作者：
Marcusa, Dan P.
Giugliano, Robert P.
Park, Jeong-Gun
Sever, Peter
Wang, Huei
Hamer, Andrew
Pedersen, Terje R.
Keech, Anthony C.
Sabatine, Marc S.
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
10.1161/circ.142.suppl_3.13200
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13200
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):
  • [2] Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition
    Marcusa, Daniel P.
    Giugliano, Robert P.
    Park, Jeong-Gun
    de Lemos, James A.
    Cannon, Christopher P.
    Sabatine, Marc S.
    JAMA CARDIOLOGY, 2021, 6 (05) : 582 - 586
  • [3] Low-density lipoprotein cholesterol reduction by inhibition of PCSK9
    Stein, Evan A.
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (06) : 510 - 517
  • [4] Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
    Bonaca, Marc P.
    Nault, Patrice
    Giugliano, Robert P.
    Keech, Anthony C.
    Pineda, Armando Lira
    Kanevsky, Estella
    Kuder, Julia
    Murphy, Sabina A.
    Jukema, J. Wouter
    Lewis, Basil S.
    Tokgozoglu, Lale
    Somaratne, Ransi
    Sever, Peter S.
    Pedersen, Terje R.
    Sabatine, Marc S.
    CIRCULATION, 2018, 137 (04) : 338 - 350
  • [5] Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9
    Stein, Evan A.
    Raal, Frederick
    ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 : 417 - 431
  • [6] PCSK9 gene mutations and low-density lipoprotein cholesterol
    Wu, Na-Qiong
    Li, Jian-Jun
    CLINICA CHIMICA ACTA, 2014, 431 : 148 - 153
  • [7] Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors
    Scherer, Daniel J.
    Nelson, Adam J.
    Psaltis, Peter J.
    Nicholls, Stephen J.
    INTERNAL MEDICINE JOURNAL, 2017, 47 (08) : 856 - 865
  • [8] Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol Metabolism: Of Mice and Man
    Stein, Evan A.
    Raal, Frederick J.
    CIRCULATION, 2013, 127 (24) : 2372 - 2374
  • [9] Letter by Alkhalil Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)"
    Alkhalil, Mohammad
    CIRCULATION, 2018, 138 (02) : 220 - 221
  • [10] Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction
    Davidson, Michael H.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (03) : S11 - S15
12345